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Fenretinide Treatment Prevents Diet-Induced Obesity
in Association With Major Alterations in Retinoid
Homeostatic Gene Expression in Adipose, Liver,
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George D. Mcilroy, Mirela Delibegovic, Carl Owen, Patrick N. Stoney, Kirsty D. Shearer,
Peter J. McCaffery, and Nimesh Mody
The synthetic retinoid, Fenretinide (FEN), inhibits obesity and
insulin resistance in mice and is in early clinical trials for treat-
ment of insulin resistance in obese humans. We aimed to deter-
mine whether alterations in retinoic acid (RA)-responsive genes
contribute to the beneﬁcial effects of FEN. We examined
the effect of FEN on 3T3-L1 adipocyte differentiation and alter-
ations in gene expression in C57Bl/6 and retinaldehyde dehydro-
genase (RALDH) 1 knockout (KO) mice fed a high-fat (HF)
diet. FEN completely inhibited adipocyte differentiation by
blocking CCAAT/enhancer-binding protein (C/EBP) a/peroxisome
proliferator–activated receptor (PPAR) g2mediated induction of
downstream genes and upregulating RA-responsive genes like
cellular retinol-binding protein-1. In mice fed an HF diet, RA-
responsive genes were markedly increased in adipose, liver,
and hypothalamus, with short-term and long-term FEN treatment.
In adipose, FEN inhibited the downregulation of PPARg and im-
proved insulin sensitivity and the levels of adiponectin, resistin,
and serum RBP (RBP4). FEN inhibited hyperleptinemia in vivo
and leptin expression in adipocytes. Surprisingly, hypothalamic
neuropeptide Y expression was completely suppressed, suggest-
ing a central effect of FEN to normalize hyperglycemia. More-
over, FEN induced RA-responsive genes in RALDH1 KO mice,
demonstrating that FEN can augment RA signaling when RA syn-
thesis is impaired. We show that FEN-mediated beneﬁcial effects
are through alterations in retinoid homeostasis genes, and these
are strong candidates as therapeutic targets for the treatment of
obesity and insulin resistance. Diabetes 62:825–836, 2013
More than one-third of United States adults areobese and at risk for development of type 2diabetes and a host of other metabolic dis-orders, including dyslipidemia and cardio-
vascular disease. Despite the development and clinical use
of many antidiabetes drugs, they are limited by adverse
effects such as ﬂuid retention, weight gain, congestive
heart failure, liver toxicity, and the potential for carcino-
genesis (1). Therefore, alternative therapies for the treat-
ment of obesity and type 2 diabetes are needed.
The synthetic retinoid, Fenretinide [N-(4-hydroxyphenyl)
retinamide] (FEN) prevents obesity and insulin resistance
in mice fed a high-fat (HF) diet (2,3). In addition, FEN
lowers serum retinol–binding protein (gene name RBP4)
levels in rodents and humans by disrupting the ternary
complex of retinol-RBP4-transthyretin and thereby by
promoting renal clearance of RBP4 (4,5). However, the
antiobesity action of FEN appears to be independent of
its ability to lower circulating levels of this protein because
FEN reduces obesity development in mice lacking RBP4
and does not appear to alter food intake or energy ex-
penditure (3). Currently, FEN is undergoing a phase II trial
for treatment of insulin resistance in obese humans with
hepatic steatosis (6). Thus, the mechanisms by which FEN
can prevent obesity and insulin resistance are of great
interest. FEN was originally developed as a chemothera-
peutic agent (7), and then was found to attenuate cancer
cell growth by mechanisms such as apoptosis and reactive
oxygen species generation. However, these effects appear
to vary in different cells (8). FEN is now the most widely
studied retinoid in clinical trials of breast cancer chemo-
prevention because of its selective accumulation in
breast tissue and its favorable toxicological proﬁle (9,10).
One mild and reversible side effect is a reduction in cir-
culating retinol levels and deﬁcits in dark adaptation
attributable to lowering of circulating RBP4 levels
(4,5,11).
Retinoid homeostasis is tightly regulated by a complex
system of enzymes and carriers that can promote the
storage of retinol in the form of retinyl esters (RBP4, cel-
lular RBP1, CRBP1, and lecithin:retinol acyltransferase);
metabolism to retinoic acid (RA) and signaling through its
receptors (retinaldehyde dehydrogenase [RALDH1], cel-
lular RA-binding protein, CRABP, and RA receptors
[RARs]); and degradation via cytochrome P450-type
enzymes (CYP26A1) (12). It has long been known that RA
potently blocks adipogenesis when introduced at early
stages of differentiation (13–15). More recently, the im-
portance of retinoid homeostasis in whole-body energy
balance and glucose homeostasis has been highlighted in
genetic knockout (KO) studies of RALDH1 (lean pheno-
type), CRBP1, and CRABP1 (obese phenotype) (16–18).
Because initial mouse studies indicated that FEN could be
a promising therapeutic agent to treat or prevent obesity,
and because insulin resistance, glucose intolerance, and
human cancer trials have demonstrated few side effects,
we sought to further investigate the mechanisms by which
FEN inhibits adiposity and alters glucose and lipid ho-
meostasis. We aimed to determine whether FEN inhibits
adipocyte differentiation and alters adipose and hepatic
gene expression, and whether alterations in retinoid
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homeostasis could contribute to the mechanism of FEN-
induced leanness in the setting of diet-induced obesity.
RESEARCH DESIGN AND METHODS
Cell culture. The 3T3-L1 preadipocytes (ZenBio) were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) with 10% bovine calf serum (16170;
Gibco) and 1% pyruvate (growth media). Differentiation was induced 2 days
postconﬂuency with DMEM containing 10% fetal bovine serum (A15-104;
PAA), 1% pyruvate, 1% penicillin/streptomycin, 1 mmol/L dexamethasone, 0.5
mmol/L 3-isobutyl-1-methylxanthine, and 10 mg/mL insulin (MDI media). MDI
media were removed after 48 h and were replaced every 2 days with MDI
media without 3-isobutyl-1-methylxanthine and dexamethasone. FEN, RA,
and rosiglitazone (ROSI) were dissolved in DMSO and added as indicated
(see ﬁgure legends). FEN was a generous gift from U. Thurneer (Cilag AG,
Switzerland). Cells were tested for viability using Resazurin assays (R&D
Systems).
Animals.Male C57BL/6 wild-type mice were from Charles River (Edinburgh,
UK). Mice were group-housed (four per box) for gene expression studies or
individually housed for food intake and calorimetry, were exposed to 12-h/
12-h light–dark, and had ad libitum access to food and water. Three-month-
old mice were randomized by body weight and were administered a 45% HF
diet (D12450B; Research Diets, New Brunswick, NJ), HF-containing 0.04%
wt/wt FEN (Research Diets), or chow diet (801722 CRM(P); Special Diets
Service) for the duration of the studies. FEN HF mice received FEN;30 mg/
kg per day. Six-week-old mice were used for the short-term diet study.
RALDH1 KO mice were generously provided by G. Duester (19); RBP4 KO
mice were provided by L. Quadro (20). Mice were killed at the end of each
experiment by cardiac exsanguination under CO2-induced anesthesia or
cervical dislocation. Hypothalamus was precisely dissected from fresh
brains on an ice-cold platform following anatomical landmarks. All tissues
were rapidly dissected, frozen in liquid nitrogen, and stored at 280°C. An-
imal procedures were approved by University of Aberdeen Ethics Review
Board and performed under license (PPL60/3951) approved by the UK Home
Ofﬁce.
Metabolic studies. Body composition was measured by dual-energy X-ray
absorptiometry (Lunar PIXIMUS-Densitometer; GE Medical Systems). Met-
abolic rate (energy expenditure) was measured by indirect, open-circuit
calorimetry (CLAMS; Columbus Instruments) during 4–6 weeks of diet. All
mice were acclimatized to monitoring cages for 3 h before measurements of
O2 consumption. Food intake was measured every 3 days from initiation of
diet for 4 weeks, during weeks 10–12 during long-term diet treatment, and
before and during short-term treatment. Serum insulin, leptin, resistin, tu-
mor necrosis factor-a, and interleukin-6 were measured using Milliplex
Adipokine Panel (MADPK-71K; Millipore) on the Luminex platform at 20
weeks of diet treatment. On all other occasions, serum leptin was measured
by ELISA (Crystal Chem). Serum glucose was measured by glucose oxidase
assay (TR15103; Thermo) after collection of blood from tail vein of live
mice.
Lipogenesis assay. The assay was performed as described previously (21).
Brieﬂy, mice fed ad libitum were killed by cervical dislocation at 18 weeks of
diet and perigonadal adipose was dissected. Adipocytes were isolated,
resuspended (2% packed cell volume), and incubated with D-[6-3H] glucose
and insulin. Triplicate assays were stopped with scintillation liquid and 3H
lipid was measured.
Gene expression analysis. Total RNA was isolated from frozen tissue or 3T3-
L1 monolayers using peqGOLD TriFast (Peqlab). Speciﬁcally for adipose,
TriFast homogenates were centrifuged and lipid layer was removed before
phase separation. cDNA was synthesized using Bioscript cDNASynthesis
Kit (Bioline), 1 mg RNA, and oligo (dT) 18 primers and random hexamer pri-
mers. Quantitative PCR was performed using GoTaq qPCR Master Mix
(Promega) and gene-speciﬁc primers on the LightCycler-480 (Roche). Rel-
ative mRNA levels were calculated using the Pfafﬂ method (22) normalized to
hypoxanthine-guanine phosphoribosyltransferase or 18S.
Immunoblotting. Frozen tissue lysates were prepared in RIPA buffer and SDS-
PAGE was performed and transferred to nitrocellulose (21). The following
antibodies were used: total insulin receptor sc-711; total Akt/protein kinase B
(PKB) sc-8312 (Santa Cruz); RBP4 (Dako); phospho-Akt/PKB 9271; phospho-
S6 4858; phospho-ERK1/2 4376; adipose triglyceride lipase (ATGL) 2138 and
HSL 4107 (Cell Signaling); and phospho-insulin receptor 44804G (Invitrogen).
Proteins were visualized using enhanced chemiluminescence and were
quantiﬁed with Image J software or Fusion imaging system and Bio-1D soft-
ware (Peqlab).
Statistical analysis. Data are presented as means6 SEM and were compared
using one-way ANOVA with post hoc tests or Student t test (when indicated in
ﬁgure legends).
RESULTS
Fenretinide inhibits 3T3-L1 differentiation. Because
RA has been shown to inhibit adipocyte differentiation, we
examined the effect of FEN on adipocyte differentiation in
3T3-L1 cells. The 1 mmol/L FEN potently inhibited 3T3-L1
differentiation (Fig. 1A). Similar inhibition was obtained
with RA, whereas the peroxisome proliferator–activated
receptor (PPAR) g activator ROSI, a potent inducer of the
adipogenic program, was used to stimulate the rate of
differentiation. Up to ﬁve-fold higher FEN did not affect
cell viability (Supplementary Fig. 1). Terminal markers of
adipogenesis aP2, CD36, adiponectin, and lipoprotein li-
pase LPL were almost completely inhibited by FEN or RA
(Fig. 1B). GLUT4 mRNA was highly expressed in differen-
tiated cells but was not detected in undifferentiated control
(2VE CONT), RA, or FEN cells (data not shown). Similar
results were obtained with the upstream intermedi-
ate markers PPARg and C/EBPa (Fig. 1C). Expression of
C/EBPb mRNA, which normally increases transiently
during early phases of adipogenesis, was not affected by
FEN or RA (Fig. 1C).
Because FEN is a synthetic retinoid, we tested its effects
on retinoid-signaling genes (Fig. 1D and 1E). RARa was
transiently upregulated with differentiation, and this was
prevented by RA only. RARg levels were downregulated
during differentiation, and this was prevented by RA or
FEN and expression levels induced above those of 2VE
CONT cells. RARb was not expressed in these cells. RA
signaling can be further regulated by several proteins
controlling retinoid metabolism that are themselves regu-
lated by RA signaling via RA response elements (RAREs)
in their promoters. CRBP1, RALDH1, and CRABP2 all
were upregulated with RA or FEN (Fig. 1E). The major
degradation enzyme for RA, CYP26A1, was markedly re-
pressed by induction of differentiation, and this trended to
be inhibited by FEN or RA. Strikingly, all the retinoid
metabolism genes examined were coordinately repressed
with ROSI treatment (Fig. 1D and 1E).
Fenretinide inhibits lipid accumulation in fully
differentiated 3T3-L1 adipocytes. Next, we tested if
FEN could reduce lipid accumulation in fully differentiated
3T3-L1 cells (Fig. 2), because FEN has been shown to in-
hibit adiposity and adipocyte lipid content in vivo (3). As
expected, RA did not affect lipid accumulation in fully
differentiated 3T3-L1 cells (15); however, FEN treatment
signiﬁcantly reduced lipid content by 26% (Fig. 2A). The
mechanism of this reduction may involve a coordinate
reduction in the expression levels of adipocyte genes fatty
acid synthase (FAS), LPL, hormone-sensitive lipase (HSL),
ATGL, leptin, and RBP4 to levels lower than in vehicle
(VEH) and/or RA-treated adipocytes (Fig. 2B and C). FEN
signiﬁcantly induced CRBP1 and RALDH1, and it induced
small increases in RARa and RARg, but it did not affect
the expression of other retinoid genes measured (Fig. 2C).
To test whether FEN-treated cells were more insulin-sen-
sitive, cells were stimulated with insulin and Akt/PKB
phosphorylation was analyzed. Akt/PKB phosphorylation
was increased 3.5-fold in FEN-treated adipocytes, in-
dicating improved insulin sensitivity (Fig. 2D).
Fenretinide improves adipokine levels in mice with
HF-induced obesity. Next, we investigated whether FEN
treatment would induce similar alterations in vivo. In
C57Bl/6 mice, FEN treatment prevented body weight gain
over the course of 20 weeks of HF feeding (Fig. 3A),
inhibited adiposity (Fig. 3B), and completely normalized
FENRETINIDE PREVENTS OBESITY
826 DIABETES, VOL. 62, MARCH 2013 diabetes.diabetesjournals.org
hyperglycemia (Table 1). FEN did not affect lean mass
(not shown). White adipose tissue (WAT) dissected from
FEN mice and the lipid layer after aqueous buffer ho-
mogenization were yellow instead of the normal white or
pink (Fig. 3C), suggesting accumulation of FEN (a retinoid
with peak UV absorbance at 300–400 nm). Similarly, clin-
ical trials for breast cancer chemoprevention have shown
FEN to selectively accumulate in breast, a characteristi-
cally fatty tissue (23,24). Thus, we tested whether FEN
was acting directly on WAT. As expected, serum leptin
levels were reduced (Table 1). Serum RBP4 levels are re-
duced with FEN treatment (2,5); however, it is not known
if FEN affects tissue RBP4 protein levels in vivo. We found
that adipose RBP4 protein levels were decreased 40% with
FEN compared with HF-fed and chow-fed mice (Table 1).
However, hepatic RBP4 protein levels were increased
compared with HF-fed mice (Table 1). Elevated levels of
serum resistin with HF feeding also were attenuated with
FEN treatment (Table 1). Circulating levels and adipose
mRNA levels of adiponectin are reduced in obesity and
insulin resistance. We found adipose adiponectin mRNA
levels were partially normalized, up 63% with FEN treat-
ment (Table 1). Thus, multiple adipose-secreted factors
that are altered and implicated in the pathology of obesity
and insulin resistance are modulated toward normality by
FEN treatment.
Fenretinide partially normalizes adipose insulin
sensitivity in mice fed HF diet. In association with
normalized glycemia, serum insulin levels also were
markedly lower in FEN-treated mice compared with HF
(Table 1). Insulin receptor (IR) protein levels are down-
regulated in obesity and insulin resistance, inversely
FIG. 1. FEN inhibits 3T3-L1 preadipocyte differentiation and upregulates retinoid responsive genes. A: Oil-red-O staining and lipid quantiﬁcation
of 3T3-L1 adipocytes differentiated for 8 days with MDI media and indicated compounds (FEN, RA, and ROSI at 1 mmol/L or DMSO as vehicle
[VEH]) added at day 0. RA was used as a known inhibitor and ROSI was used as a promoter of differentiation. Middle panels show 403 images of
representative cell morphology and staining from six-well plate (left panel). Total lipid was quantiﬁed by eluting the stain and measuring ab-
sorbance at 520 nm (right panel). Signiﬁcance (P < 0.05 by one-way ANOVA followed by Tukey post hoc test or t test if indicated) is shown by
*ROSI, FEN, or RA compared with VEH or #FEN compared with RA. B: Gene expression of terminal adipocyte markers at day 8 of 3T3-L1 dif-
ferentiation observed in cell treatments shown in (A: undifferentiated control [2VE CONT], clear bar; VEH, black bar; ROSI, red bar; FEN, orange
bar; RA, green bar). aP2, CD36, and adiponectin FEN compared with VEH trended to be signiﬁcantly different by t test (P = 0.097, 0.086, and 0.051,
respectively). C: Early gene marker proﬁle of key transcription factors involved in the induction of adipogenesis. Cells were treated with MDI
media and the indicated compounds as in (A). Relative expression of genes was measured at the indicated time points. D and E: Gene expression
proﬁle of retinoid metabolism–related genes. Time points indicate day of differentiation from cell treatments shown in (A). The t test was used to
calculate signiﬁcant difference for RARg on day 2 and 4, ROSI compared with VEH and on day 8, FEN vs. VEH and for CRBP1 on day 2, 4, and 8,
FEN compared with VEH and on day 4 and 8 ROSI vs. VEH. Otherwise signiﬁcance was calculated by ANOVA. Gene expression was analyzed by
quantitative PCR analysis. MDI values were removed because no signiﬁcant differences were observed between MDI 6 VEH in all cases. Data
represents mean 6 SEM of three separate experiments (performed on different days and different passage cells). (A high-quality digital repre-
sentation of this ﬁgure is available in the online issue.)
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correlating with circulating insulin levels (25,26). We
found adipose IR protein levels to be downregulated in HF
(Fig. 3D, left panel), inversely correlating with obesity (not
shown) and serum insulin levels (Fig. 3D, right panel), and
this decrease was attenuated with FEN treatment. Thus,
we measured insulin-stimulated lipogenesis in WAT ex
vivo as an indicator of WAT insulin sensitivity. Basal li-
pogenesis in WAT was not altered in HF or FEN HF mice;
however, insulin-stimulated lipogenesis was markedly de-
creased in HF mice and normalized ;40% in FEN HF mice
(Fig. 3E). Moreover, in mice injected with a bolus of in-
sulin, adipose tissue phosphorylation of Akt/PKB trended
to be higher, whereas phosphorylation of p70 S6 kinase
substrate S6 and of ERK1/2 were signiﬁcantly decreased
(Fig. 3F). S6 kinase is implicated in negative feedback in-
hibition of insulin signaling, and mice lacking adipose
mTORC1–S6 kinase signaling or whole-body ERK1 are
lean. Muscle insulin signaling was unaltered (Supplemen-
tary Fig. 2). Together, these ﬁndings indicate that
improvements in adipose insulin signaling are part of the
mechanism by which FEN exerts its beneﬁcial action.
FEN alters adipose and hepatic gene expression.
Next, we examined other metabolic genes in WAT that
may be altered by HF feeding, obesity, and insulin re-
sistance. We found PPARg and C/EBPa were decreased
;50% with HF diet, whereas the decrease in FEN was
FIG. 2. Identiﬁcation of divergent effects of FEN in fully differentiated adipocytes. A: Differentiated 3T3-L1 adipocytes were used to determine if
FEN could reduce lipid content of mature adipocyte cells. 3T3-L1 cultures were differentiated with MDI alone for 8 days and then were subjected
to the indicated treatments for an additional 8 days (FEN, RA, and ROSI at 1 mmol/L). Oil-red-O staining and lipid accumulation quantiﬁcation of
3T3-L1 adipocytes revealed FEN signiﬁcantly reduced triglyceride levels, unlike RA, which did not signiﬁcantly change. MDI plus VEH had
equivalent DMSO added as treated cells. Middle panels show 403 images of representative cell morphology/staining from six-well plate (left
panel). Total lipid was quantiﬁed by eluting the stain and measuring absorbance at 520 nm (right panel). All graphs represent mean 6 SEM of
three separate experiments (performed on different plates of cells). Signiﬁcance (P< 0.05 by one-way ANOVA followed by Tukey post hoc test or t
test if indicated) is shown for *ROSI, FEN, or RA compared with vehicle (VEH) or for #FEN vs. RA. B: Relative expression levels of adipocyte genes
observed from cultures described in (A) (quantitative PCR analysis, left panel). Immunoblots of HSL and ATGL protein levels (right panel). The t
test was used to calculate signiﬁcant difference for ATGL FEN or ROSI compared with VEH. HSL FEN vs. VEH trended to be signiﬁcantly different
by t test (P = 0.06). N = 2 different plates of cells. Otherwise signiﬁcance was calculated by ANOVA. C: Retinoid metabolism gene expression levels
observed in 3T3-L1 cultures shown in (A). The t test was used to calculate signiﬁcant difference for RARg FEN or RA vs. VEH, for CRBP1 FEN vs.
VEH, RALDH1 ROSI or FEN vs. VEH, and CYP26A1 ROSI vs. VEH. Otherwise signiﬁcance was calculated by ANOVA. D: Differentiated 3T3-L1
adipocytes were stimulated with 10 nmol/L insulin (for 15 min after overnight serum-free media) or saline (S) to determine if Fenretinide could
increase insulin sensitivity of mature adipocyte cells. Phosphorylation of Akt/PKB at Ser473 and total Akt/PKB protein expression were de-
termined by immunoblotting and the signal quantiﬁed. n = 2 different plates of cells. (A high-quality digital representation of this ﬁgure is
available in the online issue.)
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signiﬁcantly less (;30%). Similar gene expression changes
were observed with IR, aP2, and LPL (Fig. 3G). GLUT4,
PEPCK, and resistin were decreased ;80–90% with HF
diet, but were three-fold higher with FEN (Fig. 3G). CD36,
leptin, and UCP1 mRNA were unaltered with FEN treat-
ment (Fig. 3G and H). Next, we tested whether FEN could
alter expression of retinoid metabolism and signaling
genes. Adipose RBP4 and RALDH1 mRNA levels were
downregulated with HF diet, and this was attenuated with
FEN, similar to PPARg levels (Fig. 3I). Strikingly, FEN
treatment strongly induced the CRBP1, RARb, and
CYP26A1 in WAT, above and beyond the levels in chow-
fed mice (Fig. 3I). Similar data were obtained from sub-
cutaneous WAT (Fig. 3J). Moreover, we found CRBP1,
RARb, and CYP26A1 were similarly upregulated in the
liver of FENmice, whereas RBP4 levels were downregulated
FIG. 3. FEN accumulates in adipose tissue and alters adipose gene expression in HF diet–fed mice. A: Body weight curves of male C57BL/6 mice fed
chow (clear circles, n = 16), HF diet (HF; black triangles, n = 24), or HF plus 0.04% wt/wt FEN (FEN-HF; gold triangles, n = 16) from 3 months of
age, signiﬁcance was calculated by one-way ANOVA Bonferroni post hoc test. *P < 0.05 vs. chow; #P < 0.05 vs. HF (except at 8 weeks of diet).
B: Body fat content at 12 weeks on diet (chow, clear bar; HF, black bar; or FEN-HF, gold bar). C: Yellow coloration of abdominal adipose tissue in
FEN-HF mice dissected after 20 weeks of diet treatment (top panel) and fat layer of adipose RIPA lysates after centrifugation (bottom panel).
D: Insulin receptor protein levels in perigonadal adipose quantiﬁed after immunoblot (left panel: chow, clear bar; HF, black bar; or FEN-HF, gold
bar). Negative correlation of IR protein levels in perigonadal adipose with serum insulin levels at 20 weeks of diet (right panel: chow, clear circles;
HF, black triangles; or FEN-HF, gold triangles). E: Insulin-stimulated adipose lipogenesis measured ex vivo in perigonadal adipose. Chow (clear
circles), HF (black triangles), or FEN-HF (gold triangles). F: Insulin-stimulated adipose signaling in vivo. Mice were fasted overnight, injected
intraperitoneally with 10 mU/g insulin or saline for 10 min and tissues dissected. Phosphorylation of IR, Akt/PKB, S6, and ERK1 were determined
by immunoblotting and signal quantiﬁed (chow, clear bar; HF, black bar; or FEN-HF, gold bar; n = 4–6 mice). The t test was used to calculate
signiﬁcant difference for p-S6 FEN vs. HF. Otherwise signiﬁcance was calculated by ANOVA. G–J: Relative expression levels in perigonadal WAT of
metabolic (G), energy expenditure (H), and retinoid homeostasis (I) genes, and in subcutaneous WAT (J), chow (clear bars), HF (black bars), or
FEN-HF (gold bars). Molecular analysis was performed from six to eight mice per dietary group. The t test was used to calculate signiﬁcant
difference for perigonadal WAT PPARg, C/EBPa, RBP4, and RALDH1 for FEN-HF vs. HF, aP2 FEN vs. chow and RARb HF vs. chow, subcutaneous
WAT PEPCK all comparisons, RARb FEN vs. HF, and CYP26A1 chow vs. HF. Otherwise signiﬁcance was calculated by ANOVA. (A high-quality
digital representation of this ﬁgure is available in the online issue.)
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(Table 2). We also found that HF-induced elevations in
liver triglycerides were substantially decreased with FEN
treatment (Table 2). These ﬁndings were linked with in-
creased expression of fatty acid transporter CD36 with
HF diet that was prevented with FEN (Table 2). Overall,
these ﬁndings suggest that long-term FEN treatment
causes partial normalization of altered metabolic gene
expression and potent induction of RA signaling in
adipose tissue and liver, despite a reduction in circulating
retinol levels.
Effect of FEN on energy expenditure, food intake,
and hypothalamic gene expression. Despite exhibiting
decreased adiposity and serum leptin levels, indirect cal-
orimetry did not show an increase in oxygen consumption
as a potential mechanism of FEN action (Fig. 4A and B).
Rather, oxygen consumption per mouse increased linearly
TABLE 1
Serum parameters and tissue levels of metabolically important secreted factors
Chow HF FEN-HF
Serum levels
Glucose (mmol/L) 11.9 6 0.7 20.9 6 0.2† 11.6 6 0.6¶
Insulin (ng/mL) 0.7 6 0.08 2.8 6 0.3† 1.6 6 0.2‡
Leptin (ng/mL) 1.3 6 0.5 14.0 6 1.2† 9.27 6 1.0†‡
Resistin (ng/mL) 2.3 6 0.4 5.0 6 0.4† 3.3 6 0.5‡
Tumor necrosis factor-a (pg/mL) 3.5 6 0.7 3.2 6 0.2 3.6 6 0.4
IL-6 (pg/mL) 47.3 6 15.1 6.8 6 1.9 16.0 6 4.2
Tissue levels (fold-change vs. chow)
RBP4, adipose protein 1.0 6 0.05 1.02 6 0.08 0.62 6 0.04†¶
RBP4, liver protein 1.0 6 0.12 0.73 6 0.06 1.07 6 0.10‡
Adiponectin, adipose mRNA 1.0 6 0.17 0.37 6 0.06† 0.60 6 0.04*‡
*P, 0.05; †P , 0.001 for HF or FEN-HF vs. chow; ‡P, 0.05 and ¶P, 0.001 for FEN vs. HF. Serum glucose was measured at 12 weeks of diet
treatment and all other factors at 20 weeks, both after 5-h food removal. Data are presented as mean 6 SEM with signiﬁcance tested using
one-way ANOVA. For adiponectin, one-way ANOVA was not signiﬁcant for FEN-HF vs. HF; however, ‡ indicates P = 0.006 with a t test.
TABLE 2
Liver gene expression and triglyceride levels
Chow HF FEN-HF
Liver triglyceride (mg/g tissue) 15.4 6 2.0 56.5 6 5.0† 29.4 6 5.7#
Metabolic genes
5-h fasted
PPARg 1.0 6 0.05 0.8 6 0.08 0.6 6 0.03*#
CD36 1.0 6 0.1 2.5 6 0.26* 1.3 6 0.21#
LPL 1.0 6 0.11 0.7 6 0.23 1.0 6 0.30
PPARa 1.0 6 0.06 0.7 6 0.04* 0.6 6 0.05*
FAS 1.0 6 0.13 0.8 6 0.19 0.5 6 0.05*
Fed ad libitum
PPARg 1.0 6 0.089 1.2 6 0.12 1.5 6 0.12*
CD36 1.0 6 0.08 2.4 6 0.40* 2.2 6 0.30*
LPL 1.0 6 0.07 1.1 6 0.19 1.1 6 0.13
PPARa 1.0 6 0.06 1.3 6 0.09 1.4 6 0.11
FAS 1.0 6 0.12 0.4 6 0.10* 0.3 6 0.05*
PEPCK 1.0 6 0.11 0.8 6 0.14 0.7 6 0.09
IR 1.0 6 0.03 0.9 6 0.05 0.9 6 0.06
Retinoid genes
5-h fasted
RBP4 1.0 6 0.05 0.9 6 0.03 0.8 6 0.04*
CRBP1 1.0 6 0.23 0.5 6 0.14 2.3 6 0.53‡
RALDH1 1.0 6 0.07 1.1 6 0.08 0.8 6 0.03‡
RARb 1.0 6 0.06 0.8 6 0.09 2.4 6 0.25†¶
CYP26A1 1.0 6 0.14 0.5 6 0.07 28.4 6 1.62†¶
Fed ad libitum
RBP4 1.0 6 0.04 0.9 6 0.05 0.7 6 0.04†‡
CRBP1 1.0 6 0.11 0.9 6 0.21 2.4 6 0.28†¶
RALDH1 1.0 6 0.08 1.4 6 0.16 1.1 6 0.06
RALDH2 1.0 6 0.13 1.0 6 0.15 1.2 6 0.16
RARa 1.0 6 0.09 1.2 6 0.04 1.3 6 0.09*
RARb 1.0 6 0.07 0.8 6 0.06 2.5 6 0.16†¶
CYP26A1 1.0 6 0.16 0.3 6 0.07 12.7 6 1.43†¶
*P , 0.05, †P , 0.001 for HF or FEN-HF vs. chow and ‡P , 0.05 and ¶P , 0.001 for FEN vs. HF. Data are presented as mean 6 SEM with
signiﬁcance tested using one-way ANOVA.
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with increased body mass in HF-fed mice (Fig. 4C) and,
thus, FEN mice had marginally lower oxygen consump-
tion, appropriate for their weight. Food intake was un-
altered with FEN treatment (Fig. 4D). In brown adipose
tissue, there was a clear upregulation of CRBP1 and
a trend for upregulation of CYP26A1 by FEN; however,
UCP1, IR, PEPCK, and RARbmRNAs were the same in HF
and FEN HF mice (Fig. 4E).
Despite not affecting energy expenditure or food intake,
we found that FEN completely suppressed hypothalamic
NPY gene expression (Fig. 4F). In addition, FEN induced
hypothalamic RALDH1, RADLH2, and RARa mRNAs, in-
dicating a central affect of FEN treatment.
Effect of short-term FEN treatment on adipose and
hepatic gene expression. The large changes in adipose
and hepatic gene expression seen in Fig. 3 were associated
with long-term FEN treatment (20 weeks), relative lean-
ness, and major improvements in glucose homeostasis.
Next, we tested whether long-term FEN treatment was
required for these effects. After 1 week of HF diet or FEN
and HF diet, both groups gained ;2 g more than mice fed
a chow diet; however, there was a trend for decreased
body weight with FEN treatment (Fig. 5A). This effect was
not associated with decreased food intake (Fig. 5B).
Strikingly, FEN prevented the HF-induced elevation in
serum leptin levels (Fig. 5C), with a similar trend for leptin
mRNA in WAT, without an effect on other metabolic genes
such as GLUT4, adiponectin, or PEPCK (Fig. 5D). In ad-
dition, FEN prevented the HF-induced decrease in CRBP1
mRNA in WAT. Short-term FEN treatment also decreased
RBP4 mRNA and induced an increase in RARb and
CYP26A1 in WAT relative to both HF-fed and chow-fed
mice (Fig. 5D). HF diet led to a characteristic marked
downregulation of hepatic SCD-1 (Fig. 5E) and a 20–30%
decrease in adipose GLUT4 (Fig. 5D) mRNA in both HF
and FEN HF mice. Hepatic PEPCK, a known target of RA
signaling, was induced in liver with short-term FEN. No
other differences in metabolic genes were observed in
liver with short-term FEN; however, CRBP1, lecithin:
retinol acyltransferase (LRAT), RARb, and CYP26A1 all
were markedly induced. In addition, we found that hypo-
thalamic NPY mRNA was reduced 29% and 14% with FEN
compared with chow diet or HF diet, respectively (Fig.
5F). Thus, short-term FEN treatment is sufﬁcient to induce
RA signaling in adipose tissue, liver, and hypothalamus.
Gene expression alterations in RALDH1 KO and
RBP4 KO mice. Mice lacking the enzyme RALDH1 are
compromised in their ability to make RA (19) and have
been shown to be resistant to obesity and insulin re-
sistance (16). We examined whether changes in gene ex-
pression induced by FEN treatment in normal mice are
similarly altered in mice lacking RALDH1. We conﬁrmed
that RALDH1 KO mice are resistant to HF-induced obesity
(Fig. 6A). In adipose tissue, key metabolic genes that are
downregulated in obesity were approximately two-fold
higher in RALDH1 KO mice. Moreover, RBP4, CRBP1, and
RARb were induced 1.5-fold to 3-fold (Fig. 6B). In liver,
CRBP1 levels were elevated two-fold; however, CYP26A1
levels were dramatically decreased (Fig. 6C). We hypoth-
esized that CYP26A1 levels were decreased to compensate
for the reduction in RA production, and thus we tested
whether FEN could induce CYP26A1mRNA in this setting.
RALDH1 KO mice administered FEN and HF diet gained
less body mass than mice fed HF diet (Fig. 6D). Strikingly,
FEN-induced elevations in CYP26A1 and RARb in both
WAT and liver (Fig. 6E). FEN lowers serum RBP4 protein
levels but also prevents obesity in RBP4 KO mice (3).
Thus, we tested whether similar gene expression alter-
ations were present in RBP4 KO mice. We found no sig-
niﬁcant changes in the expression of retinoid metabolism
and signaling genes in liver or PG-WAT (Fig. 6F), strongly
suggesting RBP4 KO and FEN treatment have largely dif-
fering modes of action to improve insulin sensitivity.
DISCUSSION
Recent studies have identiﬁed important regulators of
retinoid homeostasis as potential therapeutic targets for
obesity (2,16–18). A major limitation to the use of retinol
or retinyl-acetate has been the development of liver dis-
ease when these compounds are used in high doses for
prolonged periods of time (27). However, FEN shows low
toxicity compared with other retinoids (7,9,24). In this
article, we show that FEN is a potent modulator of retinoid
homeostasis genes in association with an improvement in
whole-body physiology and in metabolically important
genes.
CRBP1, RARb, and CYP26A1 are known RA-responsive
genes because of the presence of RAREs located in their
respective promoter regions. The upregulation of these
proteins is thought to simultaneously promote the catab-
olism of RA and storage of retinol into retinyl-esters,
thereby preventing the toxic effects of excess RA signaling
mediated via RARs. These markers of RA signaling were
found to be upregulated with long-term (20 weeks) or
short-term (7 days) FEN treatment in all tissues examined
(adipose, liver, and hypothalamus) and 3T3-L1 adipocytes.
CYP26A1 and CRBP1 also were upregulated in cancer
cells treated with FEN (28). Moreover, FEN-induced ele-
vations in CYP26A1 and RARb independently of RALDH1
activity in HF-fed mice (Fig. 6E), indicating that increased
RA production via RALDH1 is not required. Thus, it
appears that FEN is directly or indirectly (or both) acting
on RAREs in the promoters of these genes.
Many studies examining the effects of FEN on growth
inhibition and apoptosis of cancer cell lines have con-
cluded that FEN and RA exert their cellular effects
through different pathways independent of RAR expres-
sion (29–31). For example, FEN and 4-MPR (the main ca-
tabolite of FEN) were found to bind poorly to recombinant
RARs in vitro and only minimally activated RAREs and
RXREs in cells (30). However, a role for the RARs has
been supported by a number of other investigators. Fanjul
et al. (32) demonstrated that 5–20 mmol/L FEN could
transactivate RARg and RARb. RARb expression is en-
hanced in normal human mammary cells after FEN ex-
posure (33), and others have documented that RARb or
RARg expression enhances FEN-mediated events (34,35).
It is not clear why these contrasting results have been
reported, but cell-type speciﬁc factors such as cofactor
expression, epigenetic silencing, or phosphorylation may
play a role (36–38).
Clearly, in 3T3-L1 cells, the differentiation process ini-
tiates a global downregulation of retinoid-responsive genes
that FEN or RA is able to completely inhibit. It has been
known that RA potently blocks adipogenesis when in-
troduced at early stages of differentiation (13–15). Our
results suggest that FEN acts similarly to RA in 3T3-L1
cells by blocking adipogenesis via inhibition of C/EBPb-
mediated transcription (39).
FEN modestly inhibited lipid accumulation in fully dif-
ferentiated adipocytes (Fig. 2). These results are in marked
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FIG. 4. FEN does not affect energy expenditure or brown adipose UCP1 but completely suppresses hypothalamic NPY. A–C: Energy expenditure of
mice during 4–6 weeks on diet during the night (indicated with black bar) and day (A), chow (clear circles), HF (black triangles), or FEN-HF (clear
triangles), average over total time measured (B), (chow, clear bar; HF, black bar; or FEN-HF, gray bar), and positive correlation with body weight
(C). N = 6–9 mice per dietary group. *P < 0.05 vs. chow by one-way ANOVA and Bonferroni post hoc test; #P < 0.05 by t test FEN-HF vs. HF.
D: Gross energy intake during 12–30 days diet (up to energy expenditure measurement). FEN vs. HF is not signiﬁcant. E and F: Relative gene
expression levels in brown adipose tissue (E) and hypothalamus (F), chow (clear bars), HF (black bars), or FEN-HF (gray bars) from mice killed
after 20 weeks on diets from 3 months of age. Molecular analysis was performed from 6–8 mice per dietary group. The t test was used to calculate
signiﬁcant difference for brown adipose tissue CYP26A1 HF vs. chow for hypothalamic RALDH1 and RARa FEN-HF vs. HF. Otherwise signiﬁcance
was calculated by ANOVA.
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contrast to those obtained with RA treatment (15), in-
dicating that the exact mechanism of FEN action is not
identical to that of RA. This may be because unlike RA,
FEN leads to a global reduction in vitamin A levels be-
cause of the blockade of retinol transport and the renal
loss of serum RBP4 in vivo. Short-term FEN treatment was
sufﬁcient to cause a downregulation in adipose RBP4 both
in C57Bl/6 mice and in RALDH1 KO mice. Importantly,
loss of RBP4 alone was not sufﬁcient to induce the gene
expression changes seen with either FEN treatment or
RALDH1 genetic deletion. Thus, the effects of FEN are not
simply attributable to its effects on RBP4 (3).
RA has been shown to inhibit leptin production or se-
cretion (or both) in cells and in rodents (40,41). Para-
doxically, RA also induces UCP1 in brown adipose tissue
to increase energy expenditure (42–44). FEN inhibited the
HF-induced elevation in leptin serum levels and directly
inhibited leptin mRNA by 75% in fully differentiated adi-
pocytes. In a clinical trial in overweight women, FEN im-
proved insulin sensitivity and decreased serum leptin
levels (45). We did not detect a difference in food intake or
an increase in energy expenditure or brown adipose tissue
UCP1 levels. However, we found that FEN completely
suppressed hypothalamic NPY expression, and a similar
decrease has been shown with a neuronal cell line treated
with RA (46). This ﬁnding provides a speciﬁc mechanism
for the complete suppression of hepatic glucose pro-
duction seen during a euglycemic-hyperinsulinemic clamp
(3) and complete normalization of HF-induced hypergly-
cemia seen in our studies and in those of Yang et al. (2),
because central administration of NPY can induce hepatic
insulin resistance (47).
The importance of retinoid homeostasis in whole-body
energy balance and glucose homeostasis has been high-
lighted in genetic KO studies (16–18). The CRBP1 and
CRABP2 ﬁndings are consistent with our own because
FEN-induced leanness is associated with robust upregu-
lation of these genes in vivo and in 3T3-L1 adipocytes. In
our studies, we conﬁrmed that mice lacking RALDH1 are
resistant to HF-induced obesity; however, adipose
RALDH1 levels were decreased with long-term HF diet
and FEN treatment partially prevented this decline.
Moreover, embryonic ﬁbroblasts from RALDH1-deﬁcient
mice are impaired in their ability to undergo adipogenesis
compared with wild-type ﬁbroblasts (16). Reduced PPARg
levels as the mechanism of impaired adipogenesis in
RALDH1 KO cells have been implicated (48). However,
this phenotype is not consistent with that of the adipose
PPARg KO mice, which are insulin resistant and experi-
ence hepatic steatosis with an HF diet (49). We found
adipose tissue of RALDH1 KO mice fed an HF diet had
higher levels of PPARg, IR, GLUT4, and adiponectin,
consistent with improved whole-body insulin sensitivity
and glucose homeostasis. Moreover, inhibition of 3T3-L1
cell adipogenesis by RA or FEN is associated with
a marked upregulation of RALDH1.
FEN is the most widely studied retinoid in clinical trials
(10) and is currently undergoing phase II clinical trials for
treatment of insulin resistance in obese humans with he-
patic steatosis (6). There is an urgent need for efﬁcient and
FIG. 5. Short-term FEN treatment inhibits HF induced hyperleptinemia and induces retinoid responsive genes. A–C: Male C57 BL/6 mice on chow
(clear circles), HF (black triangles), or FEN-HF (clear triangles) for 1 week from 6 weeks age, n = 8 for each diet group. Body weight curves (A) and
food intake (B) represented as gross energy intake (left panel) and change in intake from baseline (right panel) and serum leptin levels after 7 days
diet (C).D–F: Relative gene expression levels in perigonadal adipose (D), liver (E), and hypothalami (F) after 7 days of diet, chow (clear bars), HF
(black bars), or FEN-HF (gray bars). Molecular analysis was performed in 6–8 mice per dietary group. Signiﬁcance indicated by *P < 0.05 vs. chow
and #P< 0.05 vs. HF. The t test was used to calculate signiﬁcant difference for perigonadal-WAT GLUT4 HF vs. chow, liver PEPCK FEN vs. HF, and
hypothalamic NPY FEN vs. HF. Otherwise signiﬁcance was calculated by ANOVA.
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nontoxic drugs to treat obesity and insulin resistance. FEN
is relatively nontoxic and has been tested in phase III trials
for cancer for periods of up to 5 years. Recently, a novel
method to synthesize retinamides has produced a large
library of N-(4-hydroxyphenyl)retinamide analogs (50).
Although these retinamides have been evaluated for
effects on tumor cells and cancer models, it might be
useful to screen them for potentially superior effects on
the metabolic syndrome. In line with recent studies that
have shown that regulators of retinoid homeostasis are
potential therapeutic targets for obesity, we present
evidence that FEN also is a potent modulator of retinoid
homeostasis genes in association with resistance to diet-
induced obesity and insulin resistance.
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